Literature DB >> 8562147

Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy.

R M Bremnes1, K Andersen, E A Wist.   

Abstract

Cancer patients' attitude to chemotherapy were compared with those of doctors, nurses and healthy controls. 98 cancer patients, 42 healthy subjects, 44 oncologists, 35 surgeons, 32 oncology nurses and 70 surgical nurses received a questionnaire presenting a hypothetical situation involving a toxic chemotherapy regimen. Each were asked to indicate the minimal benefit with respect to chance of cure, life prolongation and symptom relief they would demand to accept the treatment. The patients and the surgical nurses were most reluctant with regard to the treatment. The subgroup of patients under 50 years which matched the oncologists, surgeons and controls with respect to age, cohabitant status and children were significantly more willing to accept the regimen than the controls and professional groups. Patients under 40 years would accept the toxic treatment with hardly any benefit as chance of cure (7%, median), life prolongation (3 months) and symptom relief (8%). Among the professionals, oncologists were most willing to accept therapy, whereas surgical nurses and surgeons were least willing.

Entities:  

Keywords:  Empirical Approach; Professional Patient Relationship

Mesh:

Year:  1995        PMID: 8562147     DOI: 10.1016/0959-8049(95)00513-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

Review 1.  Decisions for lung cancer chemotherapy: the influence of physician and patient factors.

Authors:  Patricia M Davidson; Moyez Jiwa; Alice J Goldsmith; Sarah J McGrath; Michelle Digiacomo; Jane L Phillips; Meera Agar; Phillip J Newton; David C Currow
Journal:  Support Care Cancer       Date:  2011-05-27       Impact factor: 3.603

2.  Eliciting patients' preferences for adjuvant chemotherapy in breast cancer: development and validation of a bedside decision-making instrument in a French Regional Cancer Centre.

Authors:  Marie-Odile Carrère; Nora Moumjid-Ferdjaoui; Marie Charavel; Alain Brémond
Journal:  Health Expect       Date:  2000-06       Impact factor: 3.377

3.  The early discontinuation of palliative chemotherapy in older patients with cancer.

Authors:  Jin Won Kim; Yu Jung Kim; Keun-Wook Lee; Hyun Chang; Jeong-Ok Lee; Kwang-Il Kim; Soo-Mee Bang; Jong Seok Lee; Cheol-Ho Kim; Jee Hyun Kim
Journal:  Support Care Cancer       Date:  2013-11-28       Impact factor: 3.603

Review 4.  Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authorities.

Authors:  Francesco Pignatti; Bertil Jonsson; Gideon Blumenthal; Robert Justice
Journal:  Mol Oncol       Date:  2014-10-16       Impact factor: 6.603

5.  Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up.

Authors:  Kerri M Clough-Gorr; Andreas E Stuck; Soe Soe Thwin; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

Review 6.  Methodological assessment of HCC literature.

Authors:  G Daniele; N Costa; V Lorusso; J Costa-Maia; I Pache; M Pirisi
Journal:  Ann Oncol       Date:  2013-04       Impact factor: 32.976

7.  The importance of good death components among cancer patients, the general population, oncologists, and oncology nurses in Japan: patients prefer "fighting against cancer".

Authors:  Mitsunori Miyashita; Sachiko Kawakami; Daiki Kato; Hideomi Yamashita; Hiroshi Igaki; Kimiko Nakano; Yujiro Kuroda; Keiichi Nakagawa
Journal:  Support Care Cancer       Date:  2014-07-05       Impact factor: 3.603

8.  Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.

Authors:  Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Lisa A Carey; Melissa A Troester; Stephanie B Wheeler
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

9.  Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.

Authors:  Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Melissa A Troester; Lisa A Carey; Stephanie B Wheeler
Journal:  Breast Cancer Res Treat       Date:  2015-07-28       Impact factor: 4.872

10.  The role of chemotherapy at the end of life: "when is enough, enough?".

Authors:  Sarah Elizabeth Harrington; Thomas J Smith
Journal:  JAMA       Date:  2008-06-11       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.